Lazard Asset Management
AGIO icon

Lazard Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Lazard Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-534
Closed -$17K – 1818
2025
Q2 		$17K Sell
534
-2,124
-80% -$64.4K ﹤0.01% 2134
2025
Q1 		$77K Buy
+2,658
New +$88.2K ﹤0.01% 1879
2022
Q4 		– Sell
-3,061
Closed -$86K – 2360
2022
Q3 		$86K Buy
3,061
+7
+0.2% +$188 ﹤0.01% 1532
2022
Q2 		$67K Buy
3,054
+124
+4% +$2.8K ﹤0.01% 1677
2022
Q1 		$84K Buy
2,930
+805
+38% +$24.6K ﹤0.01% 1479
2021
Q4 		$69K Buy
2,125
+12
+0.6% +$483 ﹤0.01% 1590
2021
Q3 		$97K Sell
2,113
-517
-20% -$25K ﹤0.01% 1433
2021
Q2 		$144K Buy
2,630
+2,580
+5,160% +$144K ﹤0.01% 1266
2021
Q1 		$2K Hold
50
– – ﹤0.01% 1802
2020
Q4 		$2K Buy
+50
New +$1.98K ﹤0.01% 1799
2020
Q3 		– Sell
-2,341
Closed -$125K – 1597
2020
Q2 		$125K Buy
2,341
+263
+13% +$12.2K ﹤0.01% 975
2020
Q1 		$73K Buy
+2,078
New +$96K ﹤0.01% 1065
2019
Q1 		– Sell
-14,300
Closed -$659K – 1140
2018
Q4 		$659K Hold
14,300
– – ﹤0.01% 773
2018
Q3 		$1.1M Sell
14,300
-34,787
-71% -$2.8M ﹤0.01% 735
2018
Q2 		$4.13M Buy
49,087
+20,555
+72% +$1.79M 0.01% 589
2018
Q1 		$2.33M Sell
28,532
-10,604
-27% -$820K ﹤0.01% 632
2017
Q4 		$2.24M Sell
39,136
-13,523
-26% -$851K ﹤0.01% 625
2017
Q3 		$3.51M Buy
52,659
+23,179
+79% +$1.39M 0.01% 577
2017
Q2 		$1.52M Buy
+29,480
New +$1.51M ﹤0.01% 635

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Lazard Asset Management's AGIO Position: Q3 2025 in Review

Lazard Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2025, closing a stake of 534 shares — an estimated $17K sold.

Lazard Asset Management first reported a position in AGIO in Q2 2017 and held it in 19 quarters. The position peaked at $4.13M in Q2 2018. 221 funds tracked by Wall St. Rank hold AGIO as of Q3 2025.

  • Lazard Asset Management reported no remaining Agios Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 534 Agios Pharmaceuticals shares in Q3 2025, an estimated $17K.
  • Lazard Asset Management first reported a position in Agios Pharmaceuticals in Q2 2017 and held it in 19 quarters.
  • Lazard Asset Management's Agios Pharmaceuticals position peaked at $4.13M in Q2 2018.
  • 221 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.